BIOMED

Global Cryopreservation Bags Market 2023 to 2035: Fueled by Advancements in Biopharmaceutical Industry - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 6, 2023
Health, Pharmaceutical, Tissue, DNA, Cryo-Cell International, Drug development, ATMP, FEP, Research, Cell, Type, Cryopreservation, Regenerative medicine, EVA, Polytetrafluoroethylene, Traction, Freezing, Patient safety, PTFE, Blood, Stem cell, BIOMED, Polyvinyl chloride, Longevity, Gene, Sartorius, PVC, Tea, Fine chemical, Medical device, Thermoplastic, Entegris, Growth

The global cryopreservation bags and freezing bags market is on the brink of a remarkable upswing, poised to achieve a compounded annual growth rate (CAGR) of 8% over the forecast period.

Key Points: 
  • The global cryopreservation bags and freezing bags market is on the brink of a remarkable upswing, poised to achieve a compounded annual growth rate (CAGR) of 8% over the forecast period.
  • The meticulously compiled report titled "The Cryopreservation Bags and Freezing Bags Market: Distribution by Type of Analyte Stored and Key Geographical Regions" provides a panoramic vista into the impending landscape of cryopreservation bags and freezing bags.
  • These entities have made significant strides in the realm of cryopreservation bags and freezing bags, thereby shaping the market landscape.
  • The cryopreservation bags and freezing bags market stands as a testament to innovation, poised to redefine the future of biological storage.

Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform

Retrieved on: 
Thursday, January 5, 2023
Innovation, Fungus, Cancer, Microsoft, Laniado Hospital, Antimicrobial resistance, Bacteria, Ministry, Therapy, Infection, Orphan, Virus, InterAction Council of Former Heads of State and Government, Ministry of Health (Saudi Arabia), BFM Business, CE, Letter, European Committee on Antimicrobial Susceptibility Testing, Parasitism, FDA, Hospital, BIOMED, Tel Aviv Stock Exchange, Prevalence, Survival, AST, Pharmaceutical industry, Antibiotics, Medical imaging, Medical device, Health, Bloodstream infections

Michael Poirier, Qualigen’s Chairman and CEO stated: “We are very encouraged by the milestones achieved and progress made to date by our partners in Israel.

Key Points: 
  • Michael Poirier, Qualigen’s Chairman and CEO stated: “We are very encouraged by the milestones achieved and progress made to date by our partners in Israel.
  • We believe NanoSynex’s AST may represent a breakthrough diagnostic test in the critical area of infectious disease.
  • Key accomplishments this year include:
    Closed majority investment transaction with our strategic partner Qualigen Therapeutics for enhanced product development and commercialization of our novel antimicrobial susceptibility test platform.
  • Completed development of our latest system design composed of disposable test cards, benchtop reader and real time data analysis software.

Palo Alto Networks Announces Medical IoT Security to Protect Connected Devices Critical to Patient Care

Retrieved on: 
Monday, December 5, 2022
Trust, Medicine, Internet, General Data Protection Regulation, Unit, Conference, GDPR, Environment, CISO, Health, Patient, ESG, Communication, HIPAA, Hospital, Critical care, PANW, GLMA: Health Professionals Advancing LGBTQ Equality, Intelligence, Unit 42, Pump, Policy, Health care, Map, AIMS, Multimedia, Health Insurance Portability and Accountability Act, USS Guadalcanal (CVE-60), Organization, Network behavior anomaly detection, IDC, Machine learning, Bell–LaPadula model, IOT, Epic Systems, Risk, Medical device, Risk management, Online shopping, Health insurance, Palo Alto Networks, BIOMED, Newsweek

Today, Palo Alto Networks (NASDAQ: PANW) announced Medical IoT Security the most comprehensive Zero Trust security solution for medical devices enabling healthcare organizations to deploy and manage new connected technologies quickly and securely.

Key Points: 
  • Today, Palo Alto Networks (NASDAQ: PANW) announced Medical IoT Security the most comprehensive Zero Trust security solution for medical devices enabling healthcare organizations to deploy and manage new connected technologies quickly and securely.
  • Medical IoT Security also provides best-in-class threat protection through seamless integration with Palo Alto Networks cloud-delivered security services, such as Advanced Threat Prevention and Advanced URL Filtering.
  • The new Palo Alto Networks Medical IoT Security uses machine learning (ML) to enable healthcare organizations to:
    Create device rules with automated security responses: Easily create rules that monitor devices for behavioral anomalies and automatically trigger appropriate responses.
  • Palo Alto Networks and the Palo Alto Networks logo are registered trademarks of Palo Alto Networks, Inc. in the United States and in jurisdictions throughout the world.

BiondVax Announces First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, June 1, 2022
Coronaviridae, European Investment Bank, Investment banking, Table, Coronavirus, Company, Program, Quality control, BIOMED, R, BVXV, NIS, Annual report, D, Security (finance), Omicron, EIB, U.S. Securities and Exchange Commission, Nasdaq, Max Planck Society, Risk, Infection, COVID-19, Genta (company), Technology transfer, MPG, Drug development, COVID19, Pharmaceutical industry, Vaccine, Cryptocurrency, Mobile phone, BiondVax

JERUSALEM, June 1, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceuticals company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today published its first quarter financial results for the quarter ended March 31, 2022 and provided a business update.

Key Points: 
  • JERUSALEM, June 1, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceuticals company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today published its first quarter financial results for the quarter ended March 31, 2022 and provided a business update.
  • Results are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.176 (NIS/$US), the rate as of the close of business on March 31, 2022.
  • Unaudited first quarter financial results will be submitted to the Securities and Exchange Commission.
  • BiondVax undertakes no obligation to revise or update any forward-looking statement for any reason.

Magneto Thrombectomy Solutions Announces Successful First-in-Human Results for Treatment of Pulmonary Embolism (PE)

Retrieved on: 
Tuesday, May 10, 2022
Transfer, Artery, Solution, Thrombectomy, Company, Stroke, Safety, Data, Leg, Patient, Pulmonary embolism, Thrombus, BGU, Aarhus University Hospital, FIH, Ben-Gurion University of the Negev, Breathe Me, BIOMED, PE, Prognosis, Efficiency, PERT, Embolism, Technology, CEO, Association of British HealthTech Industries, Medical imaging, Pharmaceutical industry, Computer data storage, Birth control, Magneto, Incentive

OR YEHUDA, Israel, May 10, 2022 /PRNewswire/ -- Magneto Thrombectomy Solutions (Magneto), a medical devices company developing innovative thrombectomy solutions for the treatment of ischemic stroke and pulmonary embolism, presented today successful first-in-human (FIH) results showing safety and feasibility of the eTrieve™ system, a novel catheter based on electric fields for removing blood clots, in patients with acute pulmonary embolism (PE). The data, presented today at Biomed Israel 2022, the premier international Life Science and HealthTech conference in Israel (May 10-12, Tel Aviv), showed a significant reduction in RV/LV ratio and alleviation of PE associated symptoms.

Key Points: 
  • "We are very pleased with our FIH results, which confirm the safety and efficiency of our innovative technology, as previously demonstrated in preclinical studies," said Benny Dilmoney, CEO of Magneto.
  • "Our novel catheter is a groundbreaking solution that can transform treatment of conditions caused by blood clots, such as pulmonary embolism.
  • PE is a rapidly growing market enhanced by the Pulmonary Embolism Response Team (PERT) approach for PE management.
  • Magneto Thrombectomy Solutions is developing innovative thrombectomy solutions for the treatment of ischemic strokes and pulmonary embolisms.

Madrigal Mental Care Develops Treatment for Post-Traumatic Stress Disorder Based on Psychedelic Drugs

Retrieved on: 
Monday, May 9, 2022
Transfer, People, Ben-Gurion University of the Negev, LSD, Psilocybin, Selective serotonin reuptake inhibitor, Tic disorder, Lysergic acid diethylamide, Department, Brain, Senior, Biochemistry, Student, Post-traumatic stress disorder, Lists of diseases, Company, Ketamine, Incubator, Nanoparticle, Depression, PayPal, Time, Cognition, Norepinephrine, Nanotechnology, Entrepreneurship, BGU, BGN, Diagnosis, Serotonin, Business development, Deutsche Telekom, Anxiety, Pharmacology, Patent, Serotonin–norepinephrine reuptake inhibitor, Wallace H. Coulter Department of Biomedical Engineering, MDMA, Trauma, Dell EMC, Mescaline, Psychotherapy, Government Hospital For Mental Care, PTSD, Technology, Research, Lockheed, Growth, Association of British HealthTech Industries, InterContinental, Online gambling, Pharmaceutical industry, BIOMED

BEER-SHEVA, Israel, May 9, 2022 /PRNewswire/ -- Madrigal Mental Care, a biopharmaceutical company developing a breakthrough delivery system for psychedelic drugs, introduces its novel nanotechnology for the treatment and prevention of post-traumatic stress disorder (PTSD) at Biomed Israel 2022, the premier international Life Science and HealthTech conference in Israel, on May 10-12, 2022, at the David InterContinental Hotel in Tel Aviv, Israel.

Key Points: 
  • "An increasing number of studies point to the advantages of using psychedelic drugs for the treatment of psychiatric disorders such as PTSD, depression, anxiety, obsessive compulsive disorder, and even addiction, with low doses," said Prof. Sintov.
  • The nanoparticles are biodegradable and provide a significant advantage over common practices in terms of stability and accuracy," stated David Gabay, Co-Founder, and Chairman of Madrigal Mental Care.
  • Based on Databridge, the psychedelic market is expected to reach 40$ billion by 2027 in the medical arena alone.
  • Madrigal Mental Care aims to redefine the future of mental health care by using cutting-edge, breakthrough nanotechnology to deliver psychedelic drugs.

BION Modernizes Dialysis Technical Operations to Improve Patient Care

Retrieved on: 
Tuesday, March 8, 2022
Nursing, Health, Medical Devices, Hospitals, Other Health, General Health, Biotechnology, Serenity, Dialysis, Hospital, Disinfectant, LinkedIn, Compliance, BIOMED, Health, Maintenance, Technology, Biomed-Lublin, Medical device, BION

BION (formerly Biomedix Dialysis) has reimagined the world of dialysis technical operations, providing efficient, cost effective strategies to maintain dialysis equipment, nationwide.

Key Points: 
  • BION (formerly Biomedix Dialysis) has reimagined the world of dialysis technical operations, providing efficient, cost effective strategies to maintain dialysis equipment, nationwide.
  • BION employs and manages teams of experienced biomedical care experts exclusively focused on dialysis equipment.
  • BION provides support for all dialysis care settings; hospitals, skilled nursing facilities, outpatient treatment centers, and home therapies.
  • BION was the catalyst for the successful completion of Serenity Blue Dialysis Care, said Serenity Blue Executive Director Ester Mbaya.

CyberMDX Healthcare Security Suite Release 5.0 Takes on the Ransomware Epidemic

Retrieved on: 
Monday, January 31, 2022
Benchmark, CEO, Attack, Patient safety, Risk, Budget, IOT, Internet, Biomedicine, Research, Philips, HDOS, SVP, Time, Industry, Research Institute of Healthcare Organization and Medical Management of Moscow Department of Healthcare, Health, Ipsos, Medical device, BIOMED, Hospital, Risk management

NEW YORK, Jan. 31, 2022 /PRNewswire/ -- CyberMDX , a leading healthcare cybersecurity provider delivering visibility and threat prevention for medical devices and clinical networks, today announced the launch of Release 5.0 for its Healthcare Security Suite solution.

Key Points: 
  • NEW YORK, Jan. 31, 2022 /PRNewswire/ -- CyberMDX , a leading healthcare cybersecurity provider delivering visibility and threat prevention for medical devices and clinical networks, today announced the launch of Release 5.0 for its Healthcare Security Suite solution.
  • Alongside the updates, CyberMDX is introducing two new usage tiers to ensure healthcare organizations have access to IoT and Medical Device Security now - regardless of time or budget constraints.
  • With the ubiquity of attacks against healthcare, the ability to action security, not just see what's there, is an absolute must."
  • Deployed worldwide, CyberMDX is designed to integrate with our customers' existing environments through its scalable, easy-to-deploy and agentless solution.

CyberMDX Healthcare Security Suite Release 5.0 Takes on the Ransomware Epidemic

Retrieved on: 
Monday, January 31, 2022
Benchmark, CEO, Attack, Patient safety, Risk, Budget, Health care, IOT, Internet, Biomedicine, Research, NEW, Philips, HDOS, SVP, Medical tourism, Time, Industry, Research Institute of Healthcare Organization and Medical Management of Moscow Department of Healthcare, Health, Ipsos, Medical device, BIOMED, Hospital, Risk management

NEW YORK, Jan. 31, 2022 /PRNewswire/ -- CyberMDX, a leading healthcare cybersecurity provider delivering visibility and threat prevention for medical devices and clinical networks, today announced the launch of Release 5.0 for its Healthcare Security Suite solution. Alongside the updates, CyberMDX is introducing two new usage tiers to ensure healthcare organizations have access to IoT and Medical Device Security now - regardless of time or budget constraints.

Key Points: 
  • Global Healthcare security leader introduces intelligent mitigation actioning into latest release - and launches two new offerings, including the industry's first IoT Security Freemium editionfor healthcare organizations who need help now
    NEW YORK, Jan. 31, 2022 /PRNewswire/ -- CyberMDX , a leading healthcare cybersecurity provider delivering visibility and threat prevention for medical devices and clinical networks, today announced the launch of Release 5.0 for its Healthcare Security Suite solution.
  • Alongside the updates, CyberMDX is introducing two new usage tiers to ensure healthcare organizations have access to IoT and Medical Device Security now - regardless of time or budget constraints.
  • With the ubiquity of attacks against healthcare, the ability to action security, not just see what's there, is an absolute must."
  • Deployed worldwide, CyberMDX is designed to integrate with our customers' existing environments through its scalable, easy-to-deploy and agentless solution.

Pixium Vision to attend BIOMED EVENT® by Invest Securities on January 26, 2022

Retrieved on: 
Thursday, January 6, 2022
Diamond, IMO, University, Research, Patient, BIOMED, Investment Securities, Institute, Security (finance), Moorfields Eye Hospital, Vance DeGeneres, UPMC, Vision Institute, Retinal degeneration, Stanford University, Rehabilitation, EN

Invest Securities on January 26, 2022

Key Points: 
  • Invest Securities on January 26, 2022
    Paris, France, January 6, 2022 07:00 CET Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that Lloyd Diamond, Chief Executive Officer of Pixium Vision, will attend the B IOMED E VENT by Invest Securities, being held on Wednesday, January 26, 2022.
  • The BIOMED EVENT by Invest Securities will host a number of European listed biotech and healthcare companies and institutional investors.
  • Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy.
  • Pixium Visions bionic vision systems are associated with a surgical intervention and a rehabilitation period.